search
Back to results

SYNchronizing Exercises, Remedies in GaIt and Cognition (SYNERGIC)

Primary Purpose

Mild Cognitive Impairment

Status
Terminated
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Vitamin D3
Exercises (E)
Cognitive Training (CT)
placebo D3
control cognitive training
Placebo exercise
Sponsored by
Lawson Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mild Cognitive Impairment focused on measuring Cognitive training, Vitamin D, Exercise

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. At least 60 years of age
  2. Self-reported levels of proficiency in English (French for Montreal site only) for speaking and understanding spoken language.
  3. Able to comply with scheduled visits, treatment plan, and other trial procedures
  4. Able to ambulate at least 10 meters independently
  5. Having MCI operationalized using Albert et al. criteria as:

    • objective cognitive impairment in one of the following four cognitive domains: memory, executive function, attention, and language evaluated by the Montreal Cognitive Assessment (MoCA) test with scores ranging from 13-24/30.
    • Preserved activities of daily living on the disability scale confirmed by clinician interview
  6. Having normal or corrected to normal vision in at least one eye so that they can identify symbols and stimuli presented on a computer screen in front of them.
  7. Must be in sufficient health to participate in the study's aerobic-based exercise training program, based on medical history, vital signs, physical examination by study physicians, or written recommendation by family physician indicating one's appropriateness to participate in aerobic-based exercise training program.

Exclusion Criteria:

  1. Serious underlying disease (such as active cancer, or recent heart attack) which, in the opinion of the investigator, may preclude engagement in interventions or may interfere with the participant's ability to participate fully in the study.
  2. Diagnosis of dementia using criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
  3. Participant with uncontrolled major depression, schizophrenia, severe anxiety and substance abuse.
  4. Current parkinsonism or any neurological disorder with residual motor deficits (e.g. stroke with motor deficit), active musculo-skeletal disorders (e.g. severe osteoarthritis of lower limbs) or history of knee/hip replacement affecting gait performance at clinical evaluation.
  5. Intention to enroll in other clinical trials during the same time period
  6. Pre-existing exercise structured training program involving aerobic or resistance training in previous 6 months.
  7. Taking cognitive enhancers, neuroleptics, anticholinergics or Vitamin D3 in doses more than 1000IU/day or equivalent.

Sites / Locations

  • University of British Columbia
  • St. Joseph's Health Care London, Parkwood Hospital
  • University of Waterloo
  • Wilfrid Laurier University
  • Université de Montréal

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Exercises+CognitiveTraining+Vitamin D3

Exercises+CognitiveTraining+Placebo D3

Exercises+Control CogTraining+Vitamin D3

Exercises+Control CogTraining+Placebo D3

Placebo exercise+Control Cog+Placebo D3

Arm Description

Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an "ad-hoc" software developed by us for tablets. Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks.

Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an "ad-hoc" software developed by us for tablets. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.

Exercises will combine aerobic+resistance training. Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc.). Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks

Exercises will combine aerobic+resistance training.Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.

This will be the comparator arm with control/placebo activities.

Outcomes

Primary Outcome Measures

Change in global cognition assessed using the ADASCog(13 and Plus modalities).
Global cognition will be assessed using the cognitive section of the Alzheimer Disease Assessment Scale-plus EF+FA (ADAS-Cog-plus). This scale consists of 10 brief cognitive tests assessing memory, language, executive function, praxis, and instrumental activities of daily living. The ADAS-Cog has been a significant outcome measure in numerous trials with MCI and AD. The ADAS-Cog-plus has marked advantages as an outcome measure in MCI populations since incorporates items concerning executive function (EF) and functional abilities (FA). Scores in the ADASCog-plus (EF+FA) range from 0 to 90, with higher scores indicating better cognitive performance.

Secondary Outcome Measures

Change in cognition assessed as the CCNA Cognitive Battery.
The Canadian Consortium on Neurodegeneration in Ageing (CCNA) has established a battery of neuropsychological test which will used as secondary outcomes
Change in gait velocity (cm/s).
Gait will be assessed under single and dual-task conditions
Change in gait variability (%CoV).
Gait will be assessed under single and dual-task conditions
Brain structure (sMRI)
Structural 3 Tesla MRI will be performed at baseline and 20 weeks in all participants who do no present contra-indication for imaging studies
Brain function (fMRI)
Functional 3 Tesla MRI will be performed at baseline and at 20 weeks 6 in all participants who do no present contra-indication for imaging studies.
Changes in BDNF serum levels
Changes in brain derived neurotrophic factor (BDNF) serum levels will be assessed and measured in international units
Combined Score of Cognition and Functionality (Pooled Index)
This index will include cognitive test, gait velocity, dual task gait and the ability to perform activities of daily living. Therefore, treatments are considered successful if they slow down the progression of cognitive decline and maintain functionality and independency
Changes in serum levels Interleukin 1.
Changes in IL-1 will be assessed in serum and measured in international units.
Changes in serum levels Interleukin 6.
Changes in IL-6 will be assessed in serum and measured in international units.
Changes in serum High Sensitive C reactive protein (CRP).
Serum levels of C reactive protein (CRP) 1 will be determined by standardized ELISA methods.
Changes in serum levels of VEGF receptor 1.
Serum levels of VEGF receptor 1 will be determined by standardized ELISA methods.

Full Information

First Posted
June 6, 2016
Last Updated
September 30, 2021
Sponsor
Lawson Health Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02808676
Brief Title
SYNchronizing Exercises, Remedies in GaIt and Cognition
Acronym
SYNERGIC
Official Title
SYNchronizing Exercises, Remedies in GaIt and Cognition (SYNERGIC): A Randomized Controlled Double Blind Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Terminated
Why Stopped
Due to the COVID-19 pandemic, in-person interventions/assessments no longer possible.
Study Start Date
July 14, 2016 (Actual)
Primary Completion Date
November 24, 2020 (Actual)
Study Completion Date
November 24, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lawson Health Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The proposed SYNERGIC trial is uniquely designed to evaluate the effect of aerobic and progressive resistance training exercises, combined with cognitive training and Vitamin D3 supplementation, in cognition and mobility in older adults with Mild Cognitive Impairment (MCI).
Detailed Description
Exercises, specifically resistance and aerobic training, have been demonstrated to improve cognitive outcomes, along with improved physical capacity and mobility. Both aerobic and resistance training trials of different duration have revealed positive results, with the most consistent findings being observed after combined interventions of 6 months to one year. Although the training benefits of progressive resistance training (PRT) have been well documented, PRT has been studied far less extensively in older adults with Mild Cognitive Impairment (MCI). Exercise training has proven to be beneficial for cognition even in vulnarable populations like in frail older adults, and those with mobility issues. The exact mechanism supporting the benefits of exercise for cognition in humans needs to be further explored, as numerous studies in animals and humans have demonstrated that aerobic exercise may have neuroprotective and neurorestorative effects. The rationale of combining aerobic and PRT as multimodal exercise intervention is supported by research that has revealed potential beneficial effects. In addition, multimodal exercise interventions have shown positive effects on muscle/lean mass, cognition and brain structure, functionality, and brain volume. Similarly cognitive training, i.e. computer based cognitive process training, has also shown positive results in improving cognition, mobility, and postural control. Several recent systematic reviews on the topic support the benefits of cognitive training. In line with exercise training, recent research on cognitive training has also supported important improvements in brain plasticity post-intervention. Finally, Vitamin D3 deficiency in older adults has been linked to cognitive dysfunction, dementia, and mobility decline. Besides its very well-known effects on muscle and bone physiology, several studies have shown a potential beneficial role of Vitamin D3 on cognitive function. Robustly designed trials, with longitudinal follow-up, have been recommended in older adults with MCI to investigate the comparative benefits of isolated Vitamin D3 supplementation, and combined with physical and cognitive training. To date, the effect of adding cognitive training and/or Vitamin D3 to a multimodal progressive exercise training for improving global cognition, executive function, memory, and gait in MCI has not been assessed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild Cognitive Impairment
Keywords
Cognitive training, Vitamin D, Exercise

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
176 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exercises+CognitiveTraining+Vitamin D3
Arm Type
Experimental
Arm Description
Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an "ad-hoc" software developed by us for tablets. Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks.
Arm Title
Exercises+CognitiveTraining+Placebo D3
Arm Type
Experimental
Arm Description
Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an "ad-hoc" software developed by us for tablets. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.
Arm Title
Exercises+Control CogTraining+Vitamin D3
Arm Type
Experimental
Arm Description
Exercises will combine aerobic+resistance training. Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc.). Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks
Arm Title
Exercises+Control CogTraining+Placebo D3
Arm Type
Experimental
Arm Description
Exercises will combine aerobic+resistance training.Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.
Arm Title
Placebo exercise+Control Cog+Placebo D3
Arm Type
Placebo Comparator
Arm Description
This will be the comparator arm with control/placebo activities.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3
Other Intervention Name(s)
Cholecalciferol
Intervention Description
Dose: 10000 IU, three times per week, orally.
Intervention Type
Other
Intervention Name(s)
Exercises (E)
Intervention Description
All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
Intervention Type
Other
Intervention Name(s)
Cognitive Training (CT)
Intervention Description
CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
Intervention Type
Other
Intervention Name(s)
placebo D3
Intervention Description
matching placebo for Vitamin D3
Intervention Type
Other
Intervention Name(s)
control cognitive training
Intervention Description
As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
Intervention Type
Other
Intervention Name(s)
Placebo exercise
Intervention Description
As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
Primary Outcome Measure Information:
Title
Change in global cognition assessed using the ADASCog(13 and Plus modalities).
Description
Global cognition will be assessed using the cognitive section of the Alzheimer Disease Assessment Scale-plus EF+FA (ADAS-Cog-plus). This scale consists of 10 brief cognitive tests assessing memory, language, executive function, praxis, and instrumental activities of daily living. The ADAS-Cog has been a significant outcome measure in numerous trials with MCI and AD. The ADAS-Cog-plus has marked advantages as an outcome measure in MCI populations since incorporates items concerning executive function (EF) and functional abilities (FA). Scores in the ADASCog-plus (EF+FA) range from 0 to 90, with higher scores indicating better cognitive performance.
Time Frame
baseline and at 20 weeks (after interventions finalised)
Secondary Outcome Measure Information:
Title
Change in cognition assessed as the CCNA Cognitive Battery.
Description
The Canadian Consortium on Neurodegeneration in Ageing (CCNA) has established a battery of neuropsychological test which will used as secondary outcomes
Time Frame
baseline at 20 weeks (after interventions finalised)
Title
Change in gait velocity (cm/s).
Description
Gait will be assessed under single and dual-task conditions
Time Frame
baseline at 20 weeks (after interventions finalised)
Title
Change in gait variability (%CoV).
Description
Gait will be assessed under single and dual-task conditions
Time Frame
baseline at 20 weeks (after interventions finalised)
Title
Brain structure (sMRI)
Description
Structural 3 Tesla MRI will be performed at baseline and 20 weeks in all participants who do no present contra-indication for imaging studies
Time Frame
baseline and at 20 weeks (after interventions finalised)
Title
Brain function (fMRI)
Description
Functional 3 Tesla MRI will be performed at baseline and at 20 weeks 6 in all participants who do no present contra-indication for imaging studies.
Time Frame
baseline and at 20 weeks (after interventions finalised)
Title
Changes in BDNF serum levels
Description
Changes in brain derived neurotrophic factor (BDNF) serum levels will be assessed and measured in international units
Time Frame
baseline and at 20 weeks (after interventions finalised)
Title
Combined Score of Cognition and Functionality (Pooled Index)
Description
This index will include cognitive test, gait velocity, dual task gait and the ability to perform activities of daily living. Therefore, treatments are considered successful if they slow down the progression of cognitive decline and maintain functionality and independency
Time Frame
baseline and at 20 weeks (after interventions finalised)
Title
Changes in serum levels Interleukin 1.
Description
Changes in IL-1 will be assessed in serum and measured in international units.
Time Frame
baseline and at 20 weeks (after interventions finalised)
Title
Changes in serum levels Interleukin 6.
Description
Changes in IL-6 will be assessed in serum and measured in international units.
Time Frame
baseline and at 20 weeks (after interventions finalised)
Title
Changes in serum High Sensitive C reactive protein (CRP).
Description
Serum levels of C reactive protein (CRP) 1 will be determined by standardized ELISA methods.
Time Frame
baseline and at 20 weeks (after interventions finalised).
Title
Changes in serum levels of VEGF receptor 1.
Description
Serum levels of VEGF receptor 1 will be determined by standardized ELISA methods.
Time Frame
baseline and at 20 weeks (after interventions finalised)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: At least 60 years of age Self-reported levels of proficiency in English (French for Montreal site only) for speaking and understanding spoken language. Able to comply with scheduled visits, treatment plan, and other trial procedures Able to ambulate at least 10 meters independently Having MCI operationalized using Albert et al. criteria as: objective cognitive impairment in one of the following four cognitive domains: memory, executive function, attention, and language evaluated by the Montreal Cognitive Assessment (MoCA) test with scores ranging from 13-24/30. Preserved activities of daily living on the disability scale confirmed by clinician interview Having normal or corrected to normal vision in at least one eye so that they can identify symbols and stimuli presented on a computer screen in front of them. Must be in sufficient health to participate in the study's aerobic-based exercise training program, based on medical history, vital signs, physical examination by study physicians, or written recommendation by family physician indicating one's appropriateness to participate in aerobic-based exercise training program. Exclusion Criteria: Serious underlying disease (such as active cancer, or recent heart attack) which, in the opinion of the investigator, may preclude engagement in interventions or may interfere with the participant's ability to participate fully in the study. Diagnosis of dementia using criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Participant with uncontrolled major depression, schizophrenia, severe anxiety and substance abuse. Current parkinsonism or any neurological disorder with residual motor deficits (e.g. stroke with motor deficit), active musculo-skeletal disorders (e.g. severe osteoarthritis of lower limbs) or history of knee/hip replacement affecting gait performance at clinical evaluation. Intention to enroll in other clinical trials during the same time period Pre-existing exercise structured training program involving aerobic or resistance training in previous 6 months. Taking cognitive enhancers, neuroleptics, anticholinergics or Vitamin D3 in doses more than 1000IU/day or equivalent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manuel M Montero-Odasso, MD, PhD
Organizational Affiliation
Gait and Brain Lab, Lawson Health Research Institute
Official's Role
Study Chair
Facility Information:
Facility Name
University of British Columbia
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
St. Joseph's Health Care London, Parkwood Hospital
City
London
State/Province
Ontario
ZIP/Postal Code
N6C5J1
Country
Canada
Facility Name
University of Waterloo
City
Waterloo
State/Province
Ontario
Country
Canada
Facility Name
Wilfrid Laurier University
City
Waterloo
State/Province
Ontario
Country
Canada
Facility Name
Université de Montréal
City
Montréal
State/Province
Quebec
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24163767
Citation
Bherer L, Erickson KI, Liu-Ambrose T. Physical exercise and brain functions in older adults. J Aging Res. 2013;2013:197326. doi: 10.1155/2013/197326. Epub 2013 Sep 17. No abstract available.
Results Reference
background
PubMed Identifier
21741129
Citation
Liu-Ambrose T, Nagamatsu LS, Voss MW, Khan KM, Handy TC. Resistance training and functional plasticity of the aging brain: a 12-month randomized controlled trial. Neurobiol Aging. 2012 Aug;33(8):1690-8. doi: 10.1016/j.neurobiolaging.2011.05.010. Epub 2011 Jul 7.
Results Reference
background
PubMed Identifier
12661673
Citation
Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci. 2003 Mar;14(2):125-30. doi: 10.1111/1467-9280.t01-1-01430.
Results Reference
background
PubMed Identifier
22929394
Citation
Langlois F, Vu TT, Chasse K, Dupuis G, Kergoat MJ, Bherer L. Benefits of physical exercise training on cognition and quality of life in frail older adults. J Gerontol B Psychol Sci Soc Sci. 2013 May;68(3):400-4. doi: 10.1093/geronb/gbs069. Epub 2012 Aug 28.
Results Reference
background
PubMed Identifier
19938164
Citation
Sage MD, Almeida QJ. A positive influence of vision on motor symptoms during sensory attention focused exercise for Parkinson's disease. Mov Disord. 2010 Jan 15;25(1):64-9. doi: 10.1002/mds.22886.
Results Reference
background
PubMed Identifier
19373930
Citation
Sage MD, Almeida QJ. Symptom and gait changes after sensory attention focused exercise vs aerobic training in Parkinson's disease. Mov Disord. 2009 Jun 15;24(8):1132-8. doi: 10.1002/mds.22469.
Results Reference
background
PubMed Identifier
17765329
Citation
Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007 Sep;30(9):464-72. doi: 10.1016/j.tins.2007.06.011. Epub 2007 Aug 31. Erratum In: Trends Neurosci. 2007 Oct;30(10):489.
Results Reference
background
PubMed Identifier
22529236
Citation
Nagamatsu LS, Handy TC, Hsu CL, Voss M, Liu-Ambrose T. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. Arch Intern Med. 2012 Apr 23;172(8):666-8. doi: 10.1001/archinternmed.2012.379. No abstract available. Erratum In: Arch Intern Med. 2013 Aug 12;173(15):1477.
Results Reference
background
PubMed Identifier
22792378
Citation
Kueider AM, Parisi JM, Gross AL, Rebok GW. Computerized cognitive training with older adults: a systematic review. PLoS One. 2012;7(7):e40588. doi: 10.1371/journal.pone.0040588. Epub 2012 Jul 11.
Results Reference
background
PubMed Identifier
22841936
Citation
Reijnders J, van Heugten C, van Boxtel M. Cognitive interventions in healthy older adults and people with mild cognitive impairment: a systematic review. Ageing Res Rev. 2013 Jan;12(1):263-75. doi: 10.1016/j.arr.2012.07.003. Epub 2012 Jul 25.
Results Reference
background
PubMed Identifier
25352805
Citation
Ballesteros S, Prieto A, Mayas J, Toril P, Pita C, Ponce de Leon L, Reales JM, Waterworth J. Brain training with non-action video games enhances aspects of cognition in older adults: a randomized controlled trial. Front Aging Neurosci. 2014 Oct 14;6:277. doi: 10.3389/fnagi.2014.00277. eCollection 2014. Erratum In: Front Aging Neurosci. 2015;7:82.
Results Reference
background
PubMed Identifier
23985135
Citation
Chapman SB, Aslan S, Spence JS, Hart JJ Jr, Bartz EK, Didehbani N, Keebler MW, Gardner CM, Strain JF, DeFina LF, Lu H. Neural mechanisms of brain plasticity with complex cognitive training in healthy seniors. Cereb Cortex. 2015 Feb;25(2):396-405. doi: 10.1093/cercor/bht234. Epub 2013 Aug 28.
Results Reference
background
PubMed Identifier
22423308
Citation
Annweiler C, Montero-Odasso M, Muir SW, Beauchet O. Vitamin D and Brain Imaging in the Elderly: Should we Expect Some Lesions Specifically Related to Hypovitaminosis D? Open Neuroimag J. 2012;6:16-8. doi: 10.2174/1874440001206010016. Epub 2012 Feb 28.
Results Reference
background
PubMed Identifier
21471466
Citation
Beauchet O, Annweiler C, Verghese J, Fantino B, Herrmann FR, Allali G. Biology of gait control: vitamin D involvement. Neurology. 2011 May 10;76(19):1617-22. doi: 10.1212/WNL.0b013e318219fb08. Epub 2011 Apr 6.
Results Reference
background
PubMed Identifier
21079183
Citation
Annweiler C, Schott AM, Rolland Y, Blain H, Herrmann FR, Beauchet O. Dietary intake of vitamin D and cognition in older women: a large population-based study. Neurology. 2010 Nov 16;75(20):1810-6. doi: 10.1212/WNL.0b013e3181fd6352.
Results Reference
background
PubMed Identifier
26495050
Citation
Montero-Odasso M, Bherer L, Studenski S, Gopaul K, Oteng-Amoako A, Woolmore-Goodwin S, Stoole P, Wells J, Doherty T, Zecevic AA, Galinsky D, Rylett RJ, Jutai J, Muir-Hunter S, Speechley M, Camicioli R. Mobility and Cognition in Seniors. Report from the 2008 Institute of Aging (CIHR) Mobility and Cognition Workshop. Can Geriatr J. 2015 Sep 30;18(3):159-67. doi: 10.5770/cgj.18.188. eCollection 2015 Sep.
Results Reference
background
PubMed Identifier
24498072
Citation
Annweiler C, Beauchet O, Bartha R, Hachinski V, Montero-Odasso M; WALK Team (Working group Angers-London for Knowledge). Vitamin D and caudal primary motor cortex: a magnetic resonance spectroscopy study. PLoS One. 2014 Jan 31;9(1):e87314. doi: 10.1371/journal.pone.0087314. eCollection 2014.
Results Reference
background
PubMed Identifier
24366243
Citation
Montero-Odasso M, Hachinski V. Preludes to brain failure: executive dysfunction and gait disturbances. Neurol Sci. 2014 Apr;35(4):601-4. doi: 10.1007/s10072-013-1613-4. Epub 2013 Dec 24.
Results Reference
background
PubMed Identifier
23110433
Citation
Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc. 2012 Nov;60(11):2127-36. doi: 10.1111/j.1532-5415.2012.04209.x. Epub 2012 Oct 30.
Results Reference
background
PubMed Identifier
22614326
Citation
Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, Gibbons LE; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012 Dec;6(4):489-501. doi: 10.1007/s11682-012-9166-3.
Results Reference
background
PubMed Identifier
21514249
Citation
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.
Results Reference
background
PubMed Identifier
17507585
Citation
Fraser SA, Li KZ, DeMont RG, Penhune VB. Effects of balance status and age on muscle activation while walking under divided attention. J Gerontol B Psychol Sci Soc Sci. 2007 May;62(3):P171-8. doi: 10.1093/geronb/62.3.p171.
Results Reference
background
PubMed Identifier
29661156
Citation
Montero-Odasso M, Almeida QJ, Burhan AM, Camicioli R, Doyon J, Fraser S, Li K, Liu-Ambrose T, Middleton L, Muir-Hunter S, McIlroy W, Morais JA, Pieruccini-Faria F, Shoemaker K, Speechley M, Vasudev A, Zou GY, Berryman N, Lussier M, Vanderhaeghe L, Bherer L. SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment. BMC Geriatr. 2018 Apr 16;18(1):93. doi: 10.1186/s12877-018-0782-7.
Results Reference
result

Learn more about this trial

SYNchronizing Exercises, Remedies in GaIt and Cognition

We'll reach out to this number within 24 hrs